Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients

Circulation

Volumn 102, Issue 17, 2000, Pages 2100-2104

  Eisenberg, Marc S ^a   Chen, Hong Jun ^a   Warshofsky, Mark K ^a   Sciacca, Robert R ^a   Wasserman, Hal S ^a   Schwartz, Allan ^a   Rabbani, LeRoy E ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Inflammation; Proteins; Survival; Transplantation

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034711125     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.17.2100     Document Type: Article

References (58)

1. The pathogenesis of atherosclerosis: A prospective for the 1990s
2. Molecular bases of the acute coronary syndromes
3. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
4. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
5. Acute phase proteins with specific reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
6. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
7. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
8. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
9. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
10. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
11. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
12. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
13. Production of C-reactive protein and risk of coronary events in stable and unstable angina
14. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
15. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
16. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
17. Retransplantation for severe accelerated coronary disease in heart transplant recipients
18. Cardiac allograft vasculopathy: Current concepts, recent developments, and future directions
19. Increased immunoreactive endothelin-1 in human transplant coronary artery disease
20. Chronic rejection: An undefined conundrum
21. Chronic vascular rejection of the heart and the kidney: Have rational treatment options emerged?
22. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection
23. Human coronary transplantation-associated arteriosclerosis: Evidence for a chronic immune reaction to activated graft endothelial cells
24. The role of inflammation in the development of allograft coronary disease
25. Coronary artery intimal thickening in the transplanted heart
26. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients
27. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiologic applications
28. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
29. Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat
30. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis
31. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection
32. Infectious causes of atherosclerosis
33. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone
34. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy
35. Vascular rejection and its relationship to allograft coronary artery disease
36. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient
37. Influence of graft rejection on incidence of accelerated graft coronary artery disease: A new approach to analysis
38. Risk factor analysis for the major hazards following heart transplantation: Rejection, infection, and coronary occlusive disease
39. Posttransplant obesity and hyperlipidemia: Major predictors of severity of coronary arteriopathy in failed human heart allografts
40. Complement activation by C-reactive protein complexes
41. CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes
42. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries
43. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
44. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
45. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7-year follow-up
46. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
47. Thrombin activity and early outcome in unstable angina pectoris
48. Endothelial cell haemostatic function after heart transplantation
49. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis
50. Plasma levels of tissue plasminogen activator and plasminogen activator inhihitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients
51. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: An immunocytochemical study
52. Effect of pravastatin on outcomes after cardiac transplantation
53. Long-term effects of pravastatin on plasma concentration of C-reactive protein
54. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction
55. Procoagulant and proinflammatory activity in acute coronary syndromes
56. Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-α, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients
57. The paradox of cytokine monitoring: Predictor of immunologic activity as well as immunologic silence following cardiac transplantation
58. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy